REG - GSK PLC - Directorate Change

GSKAnnouncement

27/09/2023 15:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230927:nRSa8765Na&default-theme=true

RNS Number : 8765N  GSK PLC  27 September 2023

Issued: 27 September 2023, London UK

 

GSK announces Wendy Becker to join the Board as Non-Executive Director

 

GSK plc (LSE/NYSE: GSK) has today announced that Wendy Becker will join the
Board of the Company as a Non-Executive Director with effect from 1 October
2023.

 

On joining the Board, Wendy will become a member of the Company's Remuneration
Committee. She will succeed Urs Rohner as Chair of the Remuneration Committee
after the Company's 2024 Annual General Meeting when Urs steps down on
completion of his nine years' service to the Board.

 

Wendy is currently Chair of Logitech International S.A., and a Board member
and Chair of the Compensation Committee of Sony Group Corporation.  She has
strong executive management experience including senior roles at McKinsey
& Company, TalkTalk, and Vodafone and as CEO at Jack Wills.  Within the
life sciences sector, Wendy is a Board member and Chair of the Remuneration
Committee of Oxford Nanopore Technologies plc. She is a member of the
governing bodies of the University of Oxford and related subsidiaries.

 

Commenting on Wendy's appointment, Sir Jonathan Symonds, Chair of GSK said: "I
am delighted to welcome Wendy to GSK. Wendy is a highly experienced
non-executive director, and has held significant leadership positions in a
wide range of global businesses, including several in the technology and life
sciences sectors. I'm sure she will make a significant contribution to the
Board and we look forward to her joining in October."

 

Notes:

 

   1.   The appointment of Wendy Becker was made by the Board on the
   recommendation of the Nominations & Corporate Governance Committee. The
   Committee conducted an extensive search and selection process for this
   appointment, using an external search firm, which is a signatory of the
   Voluntary Code of Conduct for Executive Search Firms. The external search firm
   provided a diverse list of candidates who were approached, evaluated and
   interviewed, against an agreed set of criteria aligned to the Board's target
   skills matrix.  The Board satisfied itself that Ms Becker had the experience
   and time available to carry out the role.

   2.   The Board has determined that Wendy Becker is an independent
   Non-Executive Director in accordance with the UK Corporate Governance Code.

   3.   Ms Becker will receive the standard basic fee for a Non-Executive
   Director of £113,800 per annum (including travel allowance).

   She will receive fees of £40,000 per annum when she succeeds Mr Rohner as
   Chair of the Remuneration Committee.

   Ms Becker will be required to build towards a share ownership requirement of
   GSK shares in accordance with the Company's shareholder approved Non-Executive
   remuneration policy.

   4.   Ms Becker will also become a member of the Audit & Risk Committee
   on her appointment.

   5.   Ms Becker does not have a service contract. She has a letter of
   appointment which may be viewed by contacting the Company Secretary at the
   Company's registered office.

   6.   There are no further disclosures to be made in respect of Ms Becker's
   appointment under Listing Rule 9.6.13R.

   7.   As of 1 October 2023 the Board of GSK will comprise:

Sir Jonathan Symonds      Non-Executive Chair
   Emma Walmsley             Chief Executive Officer
   Julie Brown               Chief Financial Officer
   Charles Bancroft          Senior Independent Non-Executive Director
   Elizabeth McKee Anderson  Independent Non-Executive Director
   Dr Hal Barron             Non-Executive Director
   Dr Anne Beal              Independent Non-Executive Director
   Wendy Becker              Independent Non-Executive Director
   Dr Hal Dietz              Independent Non-Executive Director
   Dr Jesse Goodman          Independent Non-Executive Director
   Urs Rohner                Independent Non-Executive Director
   Dr Vishal Sikka           Independent Non-Executive Director

 

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 GSK enquiries
 Media:               Tim Foley          +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn     +1 202 603 5003       (Washington DC)

 Investor Relations:  Nick Stone         +44 (0) 7717 618834   (London)
                      James Dodwell      +44 (0) 20 8047 2406  (London)
                      Mick Readey        +44 (0) 7990 339653   (London)
                      Josh Williams      +44 (0) 7385 415719   (London)
                      Camilla Campbell   +44 (0) 7803 050238   (London)
                      Steph Mountifield  +44 (0) 7796 707505   (London)
                      Jeff McLaughlin    +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco   +1 215 751 4855       (Philadelphia)

 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described under
Item 3.D 'Risk factors" in the company's Annual Report on Form 20-F for 2022,
and Q2 Results for 2023 and any impacts of the COVID-19 pandemic.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAXDLFLXKLFBBQ